Boston Life Sciences Roundtable
The Next Phase: Capital Strategy & Regulatory Alignment

Tuesday, June 9, 2026

Join Sidley’s Life Sciences team for an afternoon of thought-provoking and engaging discussions touching on the latest trends and hot topics including the current administration, emerging technologies, the investment landscape, and more.

Featured Panel Topics

Pipelines and Product Launches: The New Normal for Strategic FDA and Pricing Planning
This panel will explore regulatory issues impacting activities critical to successful product launches and exits today, including regulatory approval, disease awareness and other pre-approval communications, reimbursement planning in the era of MFN policy considerations, relationships with investigators, and continued access for clinical trial patients following product approval but before formulary access.

• Torrey Cope, Partner, Food, Drug and Medical Device
• Meena Datta, Partner, Global Co-leader, Healthcare

Regulated, Risky, or Revolutionary? AI's Role Across Drug Discovery, Devices, and Wellness
This panel will discuss regulatory issues, business plans, and risk-mitigation strategies for investors and companies as they scale and commercialize AI tools.

• Deeona Gaskin, Partner, Food, Drug and Medical Device and Former Associate Chief Counsel for Enforcement, FDA
• Michael Rohr, Partner, Emerging Companies and Venture Capital

Life Sciences Dealmaking in 2026: Where Capital and Collaboration Converge
This panel will discuss the evolving biotech transaction landscape, from venture financings to strategic alliances.

• Jason Kropp, Partner, Emerging Companies and Venture Capital
• Rosemary Reilly, Partner, Emerging Companies and Venture Capital

FIRESIDE CHAT
"Navigating the New Environment in DC: New Advocacy Options for Life Sciences Companies at FDA and Beyond"

A conversation with former Senior White House Official Trent Morse and Becky Wood, co-leader of Sidley's FDA Practice and former FDA Chief Counsel.

Agenda
Registration:  1:30 p.m. ET
Program: 2:00 p.m. ET
Reception: 5:00 p.m. ET

Who Should Attend?
Executives, Investors, General Counsel, and Company Counsel